Evaluation of primary musculocutaneous Hodgkin’s lymphoma with the aid of 18F FDG PET/CT – a rare entity

Authors

DOI:

https://doi.org/10.15584/ejcem.2024.2.26

Keywords:

cutaneous lymphoma, muscular lymphoma, musculocutaneous Hodgkin’s lymphoma, refractory

Abstract

Introduction and aim. Primary musculocutaneous lymphoma is extremely rare and associated with poor prognosis. Here, we present a case of refractory primary muscular lymphoma with overlying cutaneous involvement with the aid of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (18F FDG PET/CT) for staging and treatment.

Description of the case. We present the case of a 52-year-old man presented with musculocutaneous Hodgkin’s lymphoma having swelling and discolored areas over the left leg and right arm associated with itchiness. Upon examination, there was scaling, erythema over the body with Gottron’s papules on knuckles and heliotrope rash. Skin and muscle biopsy were suggestive of Hodgkin’s lymphoma. This patient was had primary musculocutaneous lymphoma. His diagnosis was delayed. PET/CT was performed for staging and response to treatment, which was suggestive of refractory disease.

Conclusion. PET/CT plays a vital role in diagnosis, staging, response to therapy and helps in optimized treatment for these specific patients.

Downloads

Download data is not yet available.

References

Gao S, Shu H, Yang H. Imaging features of skeletal muscle lymphoma: a case report and literature review. BMC Med Imaging. 2021;21(1):136. doi: 10.1186/s12880-021-00667-4

Balogova S, Greksak R, Mizickova M, Noskovicova L, Babal P, Lukac L. Case Report: Skeletal Muscle Lymphoma as a Result of Slow Centrifugal Migration of Untreated Primary Neurolymphomatosis? Front Nucl Med. 2022;2:804421. doi: 10.3389/fnume.2022.804421

Alamdari A, Naderi N, Peiman S, Shahi F. Non-Hodgkin lymphoma with primary involvement of skeletal muscle. Int J Hematol Oncol Stem Cell Res. 2014;8(3):55-57.

Kamura Y, Tsutsumi I, Miura Y, et al. Primary Intramuscular Classic Hodgkin Lymphoma: A Rare Case Report. Intern Med. 2021;60(23):3789-3793. doi:10.2169/internalmedicine.7524-21

Hakkou D, Belefqih I, Sabri S, et al. Primary Cutaneous Hodgkin’s Lymphoma: An Extremely Rare Entity. Cureus. 2021;13(11):19272 doi: 10.7759/cureus.19272

Huang J, Pang WS, Lok V, et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol. 2022;15(1):57. doi:10.1186/s13045-022-01281-9

Ansell SM, Armitage JO. Management of Hodgkin Lymphoma. Mayo Clinic Proceedings. 2006;81(3):419-426. doi: 10.4065/81.3.419

Hansmann ML, Willenbrock K. WHO classification of Hodgkin's lymphoma and its molecular pathological relevance. Pathologe. 2002;23(3):207-218. doi: 10.1007/s00292-002-0529-1

Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704-715. doi: 10.1002/ajh.25071

Massaro F, Ferrari A, Zendri E, Zanelli M, Merli F. Atypical cutaneous lesions in advanced-stage Hodgkin lymphoma: A case report. World J Clin Cases. 2019;7(17):2513-2518. doi: 10.12998/wjcc.v7.i17.2513

Pagliaro JA, White SI. Specific skin lesions occurring in a patient with Hodgkin’s lymphoma. Australas J Dermatol. 1999;40(1):41-43. doi: 10.1046/j.1440-0960.1999.00315.x

Hsia CC, Howson-Jan K, Rizkalla KS. Hodgkin lymphoma with cutaneous involvement. Dermatology Online Journal. 2009;15(5):5. doi: 10.5070/d35502h87w

Introcaso CE, Kantor J, Porter DL, Junkins-Hopkins JM. Cutaneous Hodgkin’s disease. J Am Acad Dermatol. 2008;58(2):295-298. doi: 10.1016/j.jaad.2005.11.1055

McDonald EO, Amanullah AA, Sang P, et al. The role of 18F-FDG PET/CT in primary cutaneous lymphoma: an educational review. Ann Nucl Med. 2023;37(6):328-348. doi: 10.1007/s12149-023-01830-3

Downloads

Published

2024-06-30

How to Cite

Kakkar, L., Singh, M. M., Deswal, S., & Thakur, P. B. (2024). Evaluation of primary musculocutaneous Hodgkin’s lymphoma with the aid of 18F FDG PET/CT – a rare entity. European Journal of Clinical and Experimental Medicine, 22(2), 452–456. https://doi.org/10.15584/ejcem.2024.2.26

Issue

Vol. 22 No. 2 (2024)

Section

CASUISTIC PAPERS

License

Copyright (c) 2024 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.